CytoCore hires SIPR for InPath campaign

CytoCore (Chicago) reported that it has engaged the public relations firm, SIPR (San Francisco), to launch a campaign for its InPath system, an early detection test for uterine/endometrial cancers. CytoCore says SIPR will advance CytoCore's product portfolio, which also includes the e2 Collector, a cell collection device for Pap tests.

"We believe SIPR's depth of experience with Silicon Valley's innovation technologies — and, in particular, the regulated life sciences — makes them uniquely capable of delivering the right message to the right market segments at the right time," said David Weisberg, CytoCore's CEO.

CytoCore develops cancer screening systems for the early detection of cervical, endometrial, and other cancers.

Novadaq CMO presents procedure

Novadaq Technologies (Toronto), a developer of medical imaging systems for the operating room, reported that Bruce Ferguson, MD, associate chief, Division of Vascular and CT Surgery at East Carolina University Heart Institute (Greenville, North Carolina) and the company's chief medical advisor, presented the SPY Intra-operative Fluorescence Vascular Angiography procedure and request for a unique ICD-9-CM Code at the Sept. 28 meeting of the Coordination and Maintenance Committee. As a result, a recommendation for a unique ICD-9-CM code is posted on the CMS web site.

The process for finalization of recommendations includes a public comment period. Final ICD-9-CM diagnosis and procedure codes for the upcoming fiscal year will be made public in the April 2007 Notice of Proposed Rulemaking to be published in the Federal Register following the pubic comment period which ends Dec. 4.